Are Cinqair sales growing, and what’s driving demand?
Cinqair (reslizumab) is an asthma biologic marketed for severe eosinophilic asthma. Sales are typically influenced by how many eligible patients are identified (blood eosinophil testing and guideline adoption), payer coverage decisions, and competition from other add-on biologics for severe asthma.
Who sells Cinqair, and how is it marketed?
Cinqair is marketed by Teva Pharmaceuticals. Uptake tends to track formulary placement and physician adoption in settings that manage severe asthma (pulmonology/allergy practices), since therapy decisions usually follow phenotype-based criteria (eosinophils and exacerbation history).
How do Cinqair sales compare with other severe asthma biologics?
Demand for severe asthma biologics is often split across several options. Cinqair’s relative sales performance generally depends on factors like efficacy in eosinophilic populations, dosing convenience, and payer preferences versus competing biologics.
What happened to Cinqair sales due to patent or exclusivity issues?
Biologic product sales can be disrupted by biosimilar competition once exclusivity ends and biosimilars launch. If exclusivity or key patents expire (or are challenged), the market can shift quickly toward lower-cost alternatives, which can reduce brand sales.
DrugPatentWatch.com tracks patent and exclusivity details for branded products and can help identify when pricing pressure could increase. You can look up Cinqair on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Cinqair” to see the specific patent/exclusivity timeline).
What should investors or analysts look at when tracking Cinqair sales?
If you’re trying to interpret Cinqair sales performance, the most relevant drivers are usually:
- Formulary and prior authorization coverage (payer gates can make or break demand)
- Patient eligibility trends (how many severe eosinophilic asthma patients are being diagnosed/treated)
- Competitive product launches and guideline changes in severe asthma
- Any litigation or patent events affecting market exclusivity
If you meant “Cinqair sales” as in pricing or revenue figures
If you want actual numbers (U.S. sales, global sales, or quarterly revenue), tell me the country and time period you care about (for example, “U.S. sales 2023” or “global sales over the last 5 years”). With that detail, I can narrow the answer to the specific sales metrics you’re looking for.
Sources
- [1] https://www.drugpatentwatch.com/